Valganciclovir

Generic Name
Valganciclovir
Brand Names
Valcyte
Drug Type
Small Molecule
Chemical Formula
C14H22N6O5
CAS Number
175865-60-8
Unique Ingredient Identifier
GCU97FKN3R
Background

Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.

Indication

Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.

Associated Conditions
Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
Associated Therapies
-
Clinical Trials
Related News

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

Phase 4
Completed
Conditions
Kidney Trasplant
First Posted Date
2002-04-29
Last Posted Date
2017-07-02
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
12
Registration Number
NCT00034385
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Valganciclovir in Congenital CMV Infants

First Posted Date
2002-03-07
Last Posted Date
2011-02-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT00031434
Locations
🇺🇸

University of Louisville, Louisville, Kentucky, United States

🇺🇸

Washington University in St. Louis, Saint Louis, Missouri, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

and more 18 locations

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
350
Registration Number
NCT00006145
Locations
🇺🇸

Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

🇺🇸

IHV Baltimore Treatment CRS, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 54 locations

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

Not Applicable
Completed
Conditions
Cytomegalovirus Retinitis
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
200
Registration Number
NCT00002222
Locations
🇺🇸

Cornell AIDS Clinical Trials Unit, New York, New York, United States

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
500
Registration Number
NCT00017784
Locations
🇺🇸

Retina - Vitreous Associates Med Group, Beverly Hills, California, United States

🇺🇸

Santa Clara Valley Med Ctr, San Jose, California, United States

🇺🇸

Quest Clinical Research, San Francisco, California, United States

and more 6 locations

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Phase 3
Completed
Conditions
Cytomegalovirus Retinitis
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2017-05-17
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT00002377
Locations
🇺🇸

Univ of California / San Diego / Dept of Pediatrics, La Jolla, California, United States

🇺🇸

St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis, New York, New York, United States

🇺🇸

New York Hosp - Cornell Med Ctr, New York, New York, United States

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy